CARISMA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.365 USD | -2.50% |
|
-9.93% | -53.58% |
| May. 09 | Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 02 | Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer | CI |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Sesen Bio's Confe...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.4
USD
Average target price
7.5
USD
Spread / Average Target
+435.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -53.58% | 58.16M | |
| +7.20% | 113B | |
| +11.07% | 106B | |
| +0.93% | 22.27B | |
| -12.35% | 22.22B | |
| -5.71% | 19.43B | |
| -37.85% | 17.87B | |
| -5.92% | 17.24B | |
| +7.77% | 14.29B | |
| +34.95% | 12.52B |
- Stock Market
- Equities
- CARM Stock
- News Carisma Therapeutics, Inc.
- Transcript : Sesen Bio, Inc. - Special Call